admin – Page 3388 – Get News Story

Rotator Cuff Injuries Market Poised for Significant Growth by 2032, Driven by Innovative Biologics and Regenerative Therapies | DelveInsight

“Rotator Cuff Injuries Market Report”

The rotator cuff injuries treatment market is expected to witness substantial growth, primarily fueled by an increasing prevalence, an aging population, advancements in minimally invasive surgical techniques, and the emergence of novel biologic therapies. Key rotator cuff repair companies, including Ortho Regenerative Technologies, Angiocrine Bioscience, Smith & Nephew, Arcuro Medical, and Atreon Orthopedics, are at the forefront of innovation, addressing the significant unmet needs.

DelveInsight’s “Rotator Cuff Injuries Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of rotator cuff injuries treatment market, historical and forecasted epidemiology, as well as rotator cuff injury treatment market forecast across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The report provides valuable insights into current treatment practices, rotator cuff injuries, emerging therapies, market share of individual treatments, and projected market size till 2032, offering a comprehensive picture of this evolving therapeutic landscape.

The rotator cuff syndrome market is experiencing notable growth, shaped by several converging trends. The rising incidence of shoulder injuries, particularly among athletes and the aging population, remains a primary driver. Regionally, the US dominates the market among 7MM, benefiting from a robust healthcare infrastructure, favorable reimbursement policies, and a high prevalence of sports-related injuries

Download the rotator cuff injuries market report to understand which factors are driving the rotator cuff injuries therapeutic market @ Rotator Cuff Injuries Market Trends.

Rotator cuff injuries represent one of the most common musculoskeletal disorders worldwide, with millions of individuals affected globally. According to epidemiological data cited in the report, the rotator cuff syndrome prevalence varies significantly by age, ranging from 5-10% in patients under 20 years to over 60% in individuals aged 80 and above. A prospective German population study revealed a 23% overall prevalence of rotator cuff tears, with rates increasing to 31% in those aged 70 and 51% in those aged 80, highlighting the strong correlation between advancing age and rotator cuff pathology. Additional risk factors include repetitive overhead activities, smoking, hypercholesterolemia, and genetic predisposition, all contributing to the progressive degeneration of tendon tissue.

Discover evolving trends in the rotator cuff injuries patient pool forecasts @ Rotator Cuff Injuries Epidemiology Analysis.

The current treatment paradigm for rotator cuff injuries follows a stepwise approach, beginning with conservative management including rest, physical therapy, and over-the-counter pain relievers such as ibuprofen and acetaminophen. When these interventions fail to provide adequate relief, physicians may administer steroid injections, though these are used judiciously due to the potential long-term weakening of tendon tissue, emphasising the rotator cuff injuries market challenges. For severe or non-responsive cases, surgical intervention becomes necessary, with options including arthroscopic tendon repair, open tendon repair, tendon transfer, and shoulder replacement for massive, irreparable tears—a factor that also significantly influences the shoulder replacement market as demand rises for advanced surgical solutions.

The rotator cuff injury treatment landscape is witnessing significant innovation, with several promising therapies in various stages of clinical development. Ortho-R/PRP, developed by Ortho Regenerative Technologies, is currently in Phase I/II trials and represents an advanced freeze-dried chitosan-platelet-rich plasma hybrid formulation designed to augment healing rates of sports and occupational injuries. The proprietary biopolymer matrix serves as a biodegradable scaffold, increasing the residency time of PRP components at the surgical site and enhancing therapeutic efficacy through the prolonged release of growth factors.

Another noteworthy candidate is E-CEL UVEC (AB-207) from Angiocrine Bioscience, an investigational cell therapy consisting of genetically modified endothelial cells derived from human umbilical cord blood vessels. This innovative approach has demonstrated accelerated healing and increased strength at the tendon-bone interface in preclinical studies and is currently progressing through Phase Ib/II clinical evaluation after receiving Investigational New Drug status from the FDA.

In a significant development in February 2025, Atreon Orthopedics received clearance for its BioCharge Autobiologic Matrix, which is designed to enhance the integrity of rotator cuff repairs and improve long-term patient outcomes. Additionally, Arcuro Medical’s SuperBall-RC system, an innovative device aimed at addressing the high re-tear rates, ranging from 20% to 40% in patients over 50, also received clearance in February 2025. This system simplifies the fixation of augmentation grafts, a process that has traditionally been technically demanding with existing surgical techniques. The BioCharge Autobiologic Matrix further expands the range of advanced biological solutions available to orthopedic surgeons. Following its expedited FDA clearance, Arcuro Medical plans a limited user release in the second quarter of 2025.

Additionally, in February 2025, ZuriMED Technologies AG announced that its FiberLocker System received FDA 510(k) clearance. This marks a significant milestone for the company and advances the technology for rotator cuff repairs. This FDA clearance is the result of years of dedicated development and collaboration, positioning ZuriMED to make a meaningful impact in the field of orthopedic soft tissue repair.

Furthermore, in December 2024, the Zimmer Biomet OsseoFit Stemless Shoulder System received FDA 510(k) clearance for total shoulder replacement. This anatomically shaped, stemless design aims to optimize bone preservation and fixation, especially important for younger and more active patients. The system was expected to be commercially available in Q1 2025.

Discover recent advancements in the rotator cuff injuries treatment landscape @ Rotator Cuff Injuries Recent Developments.

The market also features established products such as Smith & Nephew’s REGENETEN Bioinductive Implant, composed of type 1 collagen, which stimulates the body’s natural healing response to induce new tendon-like tissue growth and disrupt disease progression across the entire spectrum of rotator cuff tears.

Looking ahead, the rotator cuff injuries market is expected to undergo significant transformation. The integration of regenerative medicine approaches, coupled with advances in surgical techniques and imaging modalities, promises to improve outcomes and reduce recovery times for patients suffering from these debilitating injuries.

DelveInsight’s comprehensive analysis provides valuable insights for stakeholders in the rotator cuff treatment landscape, including detailed patient-based market forecasting, therapeutic approaches, pipeline analysis, market opportunities, and the impact of upcoming therapies. The rotator cuff repair market forecast across seven major markets, combined with in-depth epidemiological segmentation and competitive analysis, offers an essential resource for understanding the evolving dynamics of this important orthopedic condition.

Table of Contents

1. Key Insights

2. Report Introduction

3. Rotator Cuff Injury Market Overview at a Glance

4. Rotator Cuff Injury Market: Future Perspective

5. Executive Summary of Rotator Cuff Injury

6. Key Events

7. Disease Background and Overview

8. Rotator Cuff Injury Market Epidemiology and Patient Population

9. Rotator Cuff Injury Market Patient Journey

10. Emerging Drugs

11. Rotator Cuff Injury: Seven Major Market Analysis

12. Key Opinion Leaders’ Views

13. Rotator Cuff Injury Market Unmet Needs

14. SWOT Analysis

15. Reimbursement and Market Access

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Related Reports

Rotator Cuff Injuries Pipeline Insight

Rotator Cuff Injury pipeline insight provides comprehensive insights about the rotator cuff injuries pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the rotator cuff injuries companies, including Novartis Pharmaceuticals and Tego Science, Inc., among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rotator Cuff Injuries Market Poised for Significant Growth by 2032, Driven by Innovative Biologics and Regenerative Therapies | DelveInsight

Lumbar Spondylolisthesis Treatment Market Projected to Witness Significant Growth by 2032, Driven by Recent Clinical Trials and FDA Approvals | DelveInsight

“Lumbar Spondylolisthesis Market Report”

The lumbar spondylolisthesis market is expected to demonstrate a promising CAGR by 2032. This growth trajectory is primarily fueled by increasing prevalence across aging populations, enhanced diagnostic capabilities, and a robust pipeline of novel therapeutic approaches by key spondylolisthesis companies including Abbott, Medtronic, Stryker, Johnson & Johnson, Zimmer Biomet, Globus Medical, NuVasive, and Orthofix leading innovation in both conservative management and surgical interventions.

DelveInsight’s “Lumbar Spondylolisthesis – Market Insight, Epidemiology And Market Forecast – 2032” report provides an in-depth understanding of lumbar spondylolisthesis, historical and forecasted epidemiology, lumbar spondylolisthesis market trends, as well as key lumbar spondylolisthesis therapeutic approaches across the 7MM. The lumbar spondylolisthesis market across 7MM is expected to experience substantial growth with a decent CAGR, with numerous pipeline therapies approaching commercialization and improving diagnostic capabilities enabling earlier intervention.

Download the lumbar spondylolisthesis market report to understand which factors are driving the therapeutic landscape @ Lumbar Spondylolisthesis Market Trends.

The epidemiological analysis presented in the report reveals some interesting insights into lumbar spondylolisthesis patient pools. Degenerative spondylolisthesis, the most common subtype, is more common in older adults, particularly women, due to age-related changes in the spine. Isthmic spondylolisthesis, on the other hand, presents earlier in life and demonstrates higher prevalence among males, particularly those engaged in activities involving repetitive spinal hyperextension. Furthermore, the US accounts for the largest patient population, followed by EU4 and the UK collectively.

DelveInsight’s report also discusses the current and emerging lumbar spondylolisthesis treatment options. The current treatment paradigm begins with conservative approaches, including physical therapy, pain management, and lifestyle modifications for grade I and II cases. For advanced or refractory conditions, surgical interventions such as decompression, spinal fusion, and minimally invasive stabilization techniques represent the standard of care.

Key marketed products include a range of spinal implants and biologics that facilitate fusion and stability restoration, with companies like Medtronic’s CD HORIZON Spinal System, Globus Medical’s RISE Platform, and NuVasive’s XLIF procedural solutions capturing significant market share. Additionally, advanced pain management solutions, including Abbott’s dorsal root ganglion stimulation systems, have shown promising results in managing chronic pain associated with spondylolisthesis.

Discover evolving trends in the lumbar spondylolisthesis treatment landscape @ Lumbar Spondylolisthesis Therapies.

Recent years have witnessed significant advancements in the lumbar spondylolisthesis treatment landscape. A fast-track designation was granted by the FDA to the BRTX-100 program (BioResporative Therapies) for the treatment of chronic lumbar disc disease in February 2025.

In March 2025, the results of a study evaluated the effectiveness of a carbon-fiber PEEK pedicle screw system combined with a TLIF cage for lumbar fusion in patients with degenerative disc disease. It found a high fusion rate (98.6%) with improved clinical outcomes, suggesting CF-PEEK may be a viable alternative to metal implants, especially for better imaging clarity in follow-ups.

Furthermore, a study published in April 2025 presents a prospective, randomized comparison of lumbar facet arthroplasty versus lumbar interbody fusion for treating spondylolisthesis over a three-year period, suggesting that lumbar facet replacement could be a viable alternative to fusion in managing degenerative spondylolisthesis.

Unlock which lumbar spondylolisthesis emerging therapy is expected to capture the largest market share in the 7MM by 2032. Visit the Lumbar Spondylolisthesis Market Insights.

Despite significant therapeutic advancements, several challenges persist in the lumbar spondylolisthesis treatment landscape. Diagnostic delays remain common, particularly in early-stage disease, where symptoms may be attributed to general lower back pain. Additionally, treatment decision-making continues to be complex, with optimal timing for surgical intervention remaining somewhat subjective. The economic burden of the condition is substantial, encompassing direct healthcare costs, lost productivity, and the management of long-term disabilities.

DelveInsight’s analysis indicates that addressing these unmet needs through enhanced diagnostic protocols, personalized treatment algorithms, and value-based care models represents significant opportunities for stakeholders in this growing market. The integration of artificial intelligence in preoperative planning and risk stratification, expansion of minimally invasive surgical techniques to broader patient populations, and the development of comprehensive care pathways that optimize both surgical and non-surgical management could further drive the lumbar spondylolisthesis treatment market

The growing emphasis on functional outcomes and patient-reported measures is driving innovation toward solutions that not only stabilize the spine but also restore normal biomechanics and improve quality of life. As research continues to elucidate the complex pathophysiology of lumbar spondylolisthesis, particularly regarding genetic factors and bone quality determinants, the next generation of targeted therapies is expected to offer more personalized and effective management strategies across the spectrum of this increasingly prevalent condition.

Table of Contents

1. Key Insights

2. Executive Summary of Lumbar Spondylolisthesis

3. Competitive Intelligence Analysis for Lumbar Spondylolisthesis

4. Lumbar Spondylolisthesis: Market Overview at a Glance

5. Lumbar Spondylolisthesis: Disease Background and Overview

6. Lumbar Spondylolisthesis Patient Journey

7. Lumbar Spondylolisthesis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Lumbar Spondylolisthesis Unmet Needs

10. Key Endpoints of Lumbar Spondylolisthesis Treatment

11. Lumbar Spondylolisthesis Marketed Products

12. Lumbar Spondylolisthesis Emerging Therapies

13. Lumbar Spondylolisthesis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Lumbar Spondylolisthesis

17. KOL Views

18. Lumbar Spondylolisthesis Market Drivers

19. Lumbar Spondylolisthesis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Lumber Spondylolisthesis pipeline insight provides comprehensive insights about the Lumber Spondylolisthesis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Lumber Spondylolisthesis companies, including Empirical Spine, DePuy Synthes (Johnson & Johnson), Medtronic PLC, Stryker Corporation, Globus Medical Inc., Zimmer Biomet, Smith & Nephew PLC, Orthofix Holding Inc., Novadip Biosciences, and Ankasa Regenerative Therapeutics, Inc., among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lumbar Spondylolisthesis Treatment Market Projected to Witness Significant Growth by 2032, Driven by Recent Clinical Trials and FDA Approvals | DelveInsight

HER2-Positive Breast Cancer Market Projected for Substantial Growth Through 2032, Driven by Recent FDA Approvals and Upcoming Clinical Trials | DelveInsight

“HER2-Positive Breast Cancer Market Report”

The HER2-positive breast cancer treatment market is witnessing significant expansion, driven by the emergence of novel targeted therapies, antibody-drug conjugates, and innovative treatment approaches by key breast cancer companies, including Roche, Daiichi Sankyo, AstraZeneca, Seagen, Gilead Sciences, Macrogenics, Zymeworks, Puma Biotechnology, Jazz Pharmaceuticals, among others.

DelveInsight’s “HER2-Positive Breast Cancer – Market Insight, Epidemiology And Market Forecast – 2032” report provides comprehensive insights into the historical and forecasted HER2-positive breast cancer epidemiological trends, current treatment paradigms, and emerging therapies across the 7MM, which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report further analyzes market drivers, barriers, and unmet medical needs to identify the most promising opportunities within the evolving HER2-positive breast cancer treatment landscape.

The US currently dominates the HER2-positive breast cancer market, accounting for USD 1.6 billion in 2023. Furthermore, the total market size in EU4 and the UK exceeded USD 800 million in 2023, with projections indicating substantial growth through 2032.

Download the HER2-positive breast cancer market report to understand which factors are driving the HER2-positive breast cancer therapeutic market @ HER2-positive breast cancer Market Trends.

HER2-positive breast cancer, which accounts for approximately 15-20% of all breast cancers, represents a historically aggressive subtype with increased risk of recurrence and metastasis if not properly treated. According to DelveInsight’s epidemiological analysis, total HER2-positive breast cancer incident cases in the 7MM were more than 100K in 2023, with this figure expected to rise throughout the forecast period (2019-2032). The HR+/HER2+ breast cancer cases were highest in the US, with approximately 44K cases, while Germany led among EU4 and UK countries with around 11K cases. Furthermore, prevalence varies by age, with most HER2-positive breast cancer cases occurring in people between 40 and 60 in the US.

Discover evolving trends in the HER2-positive breast cancer patient pool forecasts @ HER2-positive breast cancer Epidemiology Analysis.

The current HER2-positive breast cancer treatment landscape has evolved significantly with the development of targeted therapies that have transformed patient outcomes. Monoclonal antibodies like HERCEPTIN (Roche and Genentech) and PERJETA (Roche) form the backbone of treatment.

The development of antibody-drug conjugates (ADCs), such as ENHERTU (Daiichi Sankyo and AstraZeneca) and KADCYLA (Roche), represents a breakthrough in treating metastatic breast cancer, particularly for HER2-positive subtypes. KADCYLA was the first ADC to gain FDA approval for breast cancer treatment, establishing itself as the standard of care in the second-line setting. In a trial in 2021, ENHERTU demonstrated superior efficacy compared to KADCYLA, establishing itself as the new standard of care in previously treated HER2-positive metastatic breast cancer.

Additionally, kinase inhibitors such as NERLYNX from Puma Biotechnology (NASDAQ: PBYI) and newer entries like MARGENZA from MacroGenics Inc. (NASDAQ: MGNX) provide options for patients who have progressed on earlier therapies.

The pipeline for HER2-positive metastatic breast cancer is expanding, with several promising candidates in late-stage development. Ambrx’s ARX788, an anti-HER2 antibody-drug conjugate (ADC), has shown statistically significant results in its prespecified interim primary efficacy endpoint during the ACE-Breast-02 trial, demonstrating greater progression-free survival compared to the active control. Additionally, Zanidatamab, an investigational bispecific antibody developed by Zymeworks and Jazz Pharmaceuticals, has produced encouraging results in combination with palbociclib and fulvestrant for HER2-positive solid tumors in an ongoing Phase II trial.

In the next 6 to 8 months, several clinical trials are expected to report results that could significantly impact current medical practices. One of the most anticipated is the DESTINY-Breast05 trial (NCT04622319), which is examining the use of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in the adjuvant setting for patients with HER2-positive breast cancer who have residual disease following neoadjuvant therapy. If successful, T-DXd could potentially replace the current standard treatment, ado-trastuzumab emtansine (T-DM1), offering a superior alternative.

Recent FDA approvals continue to reshape treatment paradigms. In April 2024, the FDA approved ENHERTU as the first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors. Further, in January 2025, ENHERTU was approved as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer.

Additionally, in February 2025, Shanghai Henlius Biotech announced that the FDA accepted its biologics license application for HLX11, a biosimilar to Roche’s PERJETA, potentially expanding treatment access and affordability.

Discover recent advancements in the HER2-positive breast cancer treatment landscape @ HER2-positive breast cancer Recent Developments.

Despite significant advancements, substantial challenges persist in the HER2-positive breast cancer treatment landscape. Brain metastases affect up to 50% of patients with metastatic HER2-positive breast cancer, significantly impacting quality of life and outcomes. Additionally, acquired resistance to current therapies remains a significant obstacle, necessitating novel approaches and rational combination strategies to overcome resistance mechanisms and extend survival for patients with advanced disease.

Looking ahead, the HER2-positive breast cancer market is positioned for continued growth through 2032, driven by biomarker-guided precision medicine approaches, innovative drug delivery systems, and rational combination regimens. The integration of technologies for real-time monitoring of treatment response and resistance development is anticipated to optimize treatment sequencing and maximize clinical outcomes for patients with this aggressive breast cancer subtype.

Table of Contents

1. Key Insights

2. Executive Summary of HER2-positive Breast Cancer

3. Competitive Intelligence Analysis for HER2-positive Breast Cancer

4. HER2-positive Breast Cancer: Market Overview at a Glance

5. HER2-positive Breast Cancer: Disease Background and Overview

6. Patient Journey

7. HER2-positive Breast Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. HER2-positive Breast Cancer Unmet Needs

10. Key Endpoints of HER2-positive Breast Cancer Treatment

11. HER2-positive Breast Cancer Marketed Products

12. HER2-positive Breast Cancer Emerging Therapies

13. HER2-positive Breast Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of HER2-positive Breast Cancer

17. KOL Views

18. HER2-positive Breast Cancer Market Drivers

19. HER2-positive Breast Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

HER2-positive breast cancer pipeline insight provides comprehensive insights about the HER2-positive breast cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the HER2-positive breast cancer companies, including Prestige BioPharma, Jiangsu HengRui Medicine Co., Ltd., Zymeworks Inc., Shanghai EXUMA Biotechnology, ORIC Pharmaceuticals, Formosa Pharmaceuticals, EirGenix, ExpreS2ion Biotechnologies, Theratechnologies, Byondis, Tanvex Biopharma, Roche, Alphamab, Biocad, Shanghai Henlius Biotech, Novartis Pharmaceuticals, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., and Zydus Cadila, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Positive Breast Cancer Market Projected for Substantial Growth Through 2032, Driven by Recent FDA Approvals and Upcoming Clinical Trials | DelveInsight

Myelodysplastic Syndrome with Excess Blasts-2 Treatment Market Expected to Strengthen Through 2032 with Emergence of Novel Therapies | DelveInsight

“Myelodysplastic Syndrome with Excess Blasts-2 Treatment Market Report”

The Myelodysplastic Syndrome with Excess Blasts-2 market is anticipated to witness substantial growth across the 7MM (United States, EU4, United Kingdom, and Japan) by 2032, primarily driven by rising disease awareness, improved diagnostic capabilities, and the development of innovative therapeutic interventions by key MDS-EB2 companies, including Sunesis Pharmaceuticals, Astellas Pharma Global Development Inc., Jazz Pharmaceuticals, Celgene, and Access Pharmaceuticals Inc., among others.

DelveInsight’s “Myelodysplastic Syndrome with Excess Blasts2 Market Insight, Epidemiology And Market Forecast – 2032” report provides an in-depth understanding of the Myelodysplastic Syndrome with Excess Blasts-2 market, including historical and forecasted epidemiology, current treatment approaches, emerging therapies, and future trends across the 7MM. The report covers the study period from 2019 to 2032, with detailed market forecasts, offering valuable insights for healthcare stakeholders, pharmaceutical companies, and investors interested in this specialized hematological market segment.

MDS-EB2, an advanced subtype of myelodysplastic syndrome (MDS), is characterized by an increased number of blasts in the bone marrow or blood and is associated with an increased risk of progression to acute myeloid leukemia (AML) compared to other MDS subtypes. The MDS-EB2 market is expected to grow significantly by 2032 with a decent CAGR. The total myelodysplastic syndrome market size was more than USD 2.8 billion across the 7MM in 2023. Furthermore, the US holds the largest market share among the 7MM. This trend is expected to continue, mainly due to higher disease awareness, favorable reimbursement, and early adoption of innovative therapies.

Download the Myelodysplastic Syndrome with Excess Blasts-2 market report to understand which factors are driving the MDS-EB2 therapeutic market @ Myelodysplastic Syndrome with Excess Blasts-2 Market Trends.

The epidemiological analysis presented in the report delivers comprehensive insights into the historical and forecasted MDS-EB2 patient pool across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. MDS-EB2 primarily affects older adults, with a male predominance. Recent classification systems have recognized the biological and clinical overlap between MDS-EB-2 and acute myeloid leukemia, leading to significant changes in how these patients are categorized.

Discover evolving trends in the Myelodysplastic Syndrome with Excess Blasts-2 patient pool forecasts @ Myelodysplastic Syndrome with Excess Blasts-2 Epidemiology Analysis.

The DelveInsight report also analyses the current and evolving MDS-EB2 treatment landscape. Current therapeutic approaches involve complex, multifaceted strategies tailored to individual patient profiles. Treatment decisions typically consider factors such as the patient’s age, overall health status, comorbidities, and specific disease characteristics. The current MDS-EB2 treatment landscape primarily consists of hypomethylating agents (HMAs) like VIDAZA (Bristol-Myers Squibb) and DACOGEN (Janssen), which have shown efficacy in improving blood counts and potentially delaying progression to AML.

The MDS-EB2 treatment pipeline is advancing rapidly, with several innovative therapies in late-stage clinical development. The most anticipated development is the completion of the phase III VERONA trial (NCT04401748) evaluating venetoclax in combination with azacitidine for high-risk MDS, including MDS-EB2, with primary results expected soon. Sabatolimab, an immune checkpoint inhibitor, also showed encouraging but not statistically significant improvements in response rates and duration in phase II trials for higher-risk MDS, with ongoing evaluation. Additionally, liposomal daunorubicin-cytarabine (CPX-351) is being tested in combination with stem cell transplantation to reduce residual disease.

These emerging therapies target various pathways involved in disease pathogenesis, potentially offering more effective and less toxic treatment options compared to conventional approaches. The report provides detailed insights into these pipeline drugs, including their mechanisms of action, clinical trial status, and anticipated launch timelines, enabling stakeholders to assess their potential impact on the future treatment landscape.

Discover recent advancements in the MDS-EB2 treatment landscape @ Myelodysplastic Syndrome with Excess Blasts-2 Recent Developments.

Looking ahead, the MDS-EB2 market is expected to evolve substantially as research advances our understanding of disease pathogenesis, leading to more personalized treatment approaches and improved patient outcomes. The integration of novel biomarkers for patient stratification and the development of combination therapies targeting specific molecular alterations represent promising directions for future research and market growth. These advancements are expected to address current unmet needs and have a significant impact on the management of this challenging hematological condition.

Table of Contents

1. Key Insights

2. Myelodysplastic Syndrome with Excess Blasts2 Executive Summary

3. Myelodysplastic Syndrome with Excess Blasts2 Competitive Intelligence Analysis

4. Myelodysplastic Syndrome with Excess Blasts2 Market Overview at a Glance

5. Myelodysplastic Syndrome with Excess Blasts2 Market Disease Background and Overview

6. Myelodysplastic Syndrome with Excess Blasts2 Patient Journey

7. Myelodysplastic Syndrome with Excess Blasts2 Epidemiology and Patient Population

8. Myelodysplastic Syndrome with Excess Blasts2 Treatment Algorithm, Current Treatment, and Medical Practices

9. Myelodysplastic Syndrome with Excess Blasts2 Unmet Needs

10. Key Endpoints of Myelodysplastic Syndrome with Excess Blasts2 Treatment

11. Myelodysplastic Syndrome with Excess Blasts2 Marketed Products

12. Myelodysplastic Syndrome with Excess Blasts2 Emerging Therapies

13. Myelodysplastic Syndrome with Excess Blasts2: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Myelodysplastic Syndrome with Excess Blasts2 Market Outlook

16. Myelodysplastic Syndrome with Excess Blasts2 Market Access and Reimbursement Overview

17. Myelodysplastic Syndrome with Excess Blasts2 KOL Views

18. Myelodysplastic Syndrome with Excess Blasts2 Market Drivers

19. Myelodysplastic Syndrome with Excess Blasts2 Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Myelodysplastic Syndrome with Excess Blasts2 Pipeline Insight provides comprehensive insights about the MDS-EB2 pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Myelodysplastic Syndrome companies, including Sunesis Pharmaceuticals, Astellas Pharma Global Development Inc., Jazz Pharmaceuticals, Celgene, Access Pharmaceuticals Inc., AbbVie Inc., Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Onconova Therapeutics, Astex Pharmaceuticals, Inc., Otsuka Pharmaceutical Co. Ltd., Lupin Pharmaceuticals, Hikma Pharmaceuticals PLC, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Celator Pharmaceuticals, Crystal Genomics Inc., Geron Co., Mylan NV, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., and MEI Pharma Inc., among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelodysplastic Syndrome with Excess Blasts-2 Treatment Market Expected to Strengthen Through 2032 with Emergence of Novel Therapies | DelveInsight

Realtor Agent In La Canada Flintridge, CA, Leverages Lifelong Local Knowledge To Navigate Changing Market

La Canada Flintridge, CA – In an increasingly complex real estate landscape, Omar Bardumyan stands out as a knowledgeable guide for buyers and sellers navigating the nuances of the local market. Having grown up in the Foothills region, Bardumyan brings a lifetime of familiarity with the area to his practice.

Since obtaining his license in 2008, Bardumyan has established himself as a top real estate agent in La Canada Flintridge, CA and a trusted advisor for clients seeking expertise in the distinctive neighborhoods that make up the community. His transition to Keller Williams Real Estate Services in 2015 further enhanced his ability to deliver results in a dynamic market.

“The advantage of growing up in this area cannot be overstated,” says Bardumyan. “I don’t just know these neighborhoods as a real estate agent – I know them as someone who has witnessed their evolution firsthand, which gives my clients valuable insights that data alone cannot provide.”

Bardumyan’s approach combines this deep-rooted local knowledge with cutting-edge market analysis. As a Realtor agent in La Canada Flintridge, CA, he leverages both traditional wisdom and modern tools to create winning strategies for his diverse clientele.

The current market presents unique challenges and opportunities that require careful navigation. “Today’s buyers and sellers need a Realtor who understands not just today’s market conditions, but how they fit into the larger context of this area’s development,” Bardumyan explains.

His comprehensive approach as a real estate selling agent in La Canada Flintridge, CA includes detailed market analyses, personalized marketing strategies, and careful attention to each client’s unique needs. This customized service has resulted in a business primarily built on referrals.

“My greatest satisfaction comes from helping people make sound real estate decisions that serve them well for years to come,” says Bardumyan. “That’s the true measure of success in this business.”

For those looking to buy or sell property in the area, Bardumyan invites them to experience the difference that local knowledge makes. Prospective clients can learn more about his services or schedule a consultation by visiting https://omarbardumyan.kw.com/.

Media Contact
Company Name: Omar Bardumyan | Real Estate Agent in La Cañada CA
Contact Person: Omar Bardumyan
Email: Send Email
Phone: +1 818 600 1787
Address:848 Foothill Blvd.
City: La Cañada Flintridge
State: California
Country: United States
Website: https://omarbardumyan.kw.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Realtor Agent In La Canada Flintridge, CA, Leverages Lifelong Local Knowledge To Navigate Changing Market

Hailey Hermida Captures Raw Emotion in New Sad Boy Music Video, Out May 2

“Photo credit: Skyler Piltch”

Today, Hailey Hermida unveils the official music video for “Sad Boy,” a raw, cinematic story of emotional unraveling and survival.

Los Angeles, CA – Hailey Hermida releases her debut music video for “Sad Boy”, premiering May 2 on YouTube.

Following the single’s release on April 10, the video captures the emotional fallout of heartbreak, paranoia, and fractured identity through a raw, stylized lens.

Directed by Julian Valdivieso, produced by Orly Morris and Elli Rosenthal, shot by Director of Photography Ian Roper, and produced through Print Night Production, the video tracks Hailey’s psychological unraveling and her slow climb toward freedom.

Drawing influence from the cinematic storytelling of early 2000s MTV, Hailey’s visual approach combines emotional depth with flashes of surreal lightness.

“This wasn’t about looking perfect. It was about making something cinematic that captured the raw emotion,” Hailey says. “It had to feel like what I actually went through and then let go of. Real life’s messy, and sometimes finding a little fun or sarcasm is the only way you get through it.”

“Sad Boy” marks an important moment in Hailey’s artistic journey, delivering her signature confessional style through powerful visuals. As she continues to evolve, Hailey is building a reputation for emotional honesty and undeniable energy both onscreen and in her live performances, pulling you straight into her world.

Premiere Date: May 2, 2025

Watch on YouTube: https://www.youtube.com/watch?v=UEjp1K8nk5Q

About Hailey Hermida

Hailey Hermida makes music for the nights when your thoughts are louder than anything playing in your headphones. The 17-year-old Los Angeles artist combines alt-pop intensity with raw emotional honesty, pulling from her inspirations Paramore’s urgency, Green Day’s edge, and Billie Eilish’s confessional storytelling. Nothing about Hailey feels manufactured. It is the kind of debut you don’t scroll past. You feel it.

Director’s Note (Julian Valdivieso)

For “Sad Boy”, we set out to create a music video that feels immersive and emotionally raw, visually echoing the song’s themes of paranoia, identity, and toxic relationships.

We leaned into a stylized look that Hailey loved, pulling from the emotional weight of classic alt-rock and pop-punk videos, while blending in my own instincts.

Shot on an ARRI ALEXA MINI with fluid zooms, steadicam instability, and medium-length primes, every technical choice matched Hailey’s emotional state in real time.

From warehouse isolation to flickering hallway silhouettes and broken mirror reflections, every frame was crafted to track her psychological unraveling and her journey back to herself.

Credits:

Director & Editor: Julian Valdivieso

Production Company: Print Night Productions

Director of Photography & Colorist: Ian Roper

AD/Producer: Orly Morris

Producer: Elli Rosenthal

Cam Op: Marcos Larancuent

AC: Bobby Wu

Gaffer: Harry Robinson

AC/G&E Swing: August Larsen-Anderson

Still Photographer: Skyler Piltch

Links

Website: haileyhermida.com
Instagram: @haileyhermida https://www.instagram.com/haileyhermida/?hl=en
TikTok: @haileyhermida https://www.tiktok.com/@haileyhermida

Media Contact
Company Name: Hailey Hermida
Contact Person: Denisse Clark
Email: Send Email
City: Los Angeles
State: CA
Country: United States
Website: http://haileyhermida.com

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Hailey Hermida Captures Raw Emotion in New Sad Boy Music Video, Out May 2

Instagram Influencer Launches Venturer Project – Global Entrepreneur Competition Offering $125K + Reality Show In BALI

“Starly Santos – Influencer Founder”

At the intersection of fashion, venture capital, and social media

Venturer Project is on a mission to empower entrepreneurs worldwide. By merging fashion with opportunity, Venturer is turning everyday dreamers into bold go-getters — offering a platform where passion meets possibility. Influencer founder, Starly Santos, was inspired by her own personal experience with the power of social media in building a brand. At the heart of Venturer’s movement is an exciting global competition open to entrepreneurs across all industries.

With a $25,000 USD investment, hands-on business mentorship, and an all-expenses-paid trip to Bali, Venturer is setting the stage for visionaries to bring their ideas to life. The ultimate winner will even have the chance to compete for an additional $100,000 investment — all while being featured in the upcoming Venturer Series, a high-energy mix of reality TV and documentary storytelling.

How It Works:

Post & Pitch – Entrepreneurs post a photo or video wearing Venturer apparel, sharing their business idea.
Get Featured – The most inspiring and viable entries are reposted to Venturer’s Instagram.
Audience Votes – The most engaged posts move to the semi-finals for interviews and business plan reviews.
Final Showdown – Four finalists receive dedicated features on Venturer’s platform, and the community votes for the winner.

What’s at Stake?

$25,000 investment in their business or idea
1-on-1 mentoring with successful founders
Exposure to 50K+ followers and potential investors
Free trip to the Venturer Villa in BALI— to network, create, & collaborate.
Spotlight in the Venturer reality competition show and a chance to win $100,000 more.

“We created Venturer to build a community of fearless go-getters who uplift and support each other,” says Starly Santos, Founder of Venturer. “This is more than just funding — it’s about providing real opportunities, mentorship, and a global stage for dreamers to thrive.”

Dare to Dream, Dare to Venture

Follow @venturerproject on Instagram, shop Venturer apparel at venturerproject.com, and start sharing your vision. The next big entrepreneur could be You. We can’t wait to hear your pitches and help amazing businesses take flight!

For more information, please visit:

https://venturerproject.com/

For media inquiries or to request an interview or guest piece, please contact:

Starly Santos

contact@venturerproject.com

Media Contact
Company Name: At Large PR
Contact Person: Jeff Bearden
Email: Send Email
Country: United States
Website: www.atlargepr.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Instagram Influencer Launches Venturer Project – Global Entrepreneur Competition Offering $125K + Reality Show In BALI

Debbie Ailiff of Procare Ambulance Named Finalist for Prestigious EY Entrepreneur Of The Year® 2025 Mid-Atlantic Award

Photo Courtesy: Debbie Ailiff / Ernst & Young LLP (EY US)

Baltimore, Maryland – April 2025 – In a significant recognition of entrepreneurial excellence, Debbie Ailiff, President and CEO of Procare Ambulance of Maryland, Inc., has been named a finalist for the Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2025 Mid-Atlantic Award. This esteemed honor celebrates visionary business leaders who drive innovation, transform industries, and create meaningful social impact.

Celebrating 40 Years of Entrepreneurial Excellence

Now in its 40th year, the Entrepreneur Of The Year program is one of the world’s most prestigious business awards, recognizing leaders who demonstrate courage, ingenuity, and a commitment to long-term value creation. The Mid-Atlantic program highlights outstanding entrepreneurs across Maryland, Virginia, and Washington, DC.

An independent judging panel selected Ailiff and 35 other finalists out of over 160 applicants, acknowledging her leadership in Procare’s mission as one of the leading medical transportation and mobile healthcare providers, aiming to deliver high-acuity interfacility transport and set valuable practices in the rapid transfer of STEMI and other critical patients. Through its innovative Mobile Integrated Healthcare (MIH) programs, Procare extends care into the home, helping reduce hospital admissions, improving outcomes, and closing critical gaps in the healthcare continuum. Procare also provides medical standby services for Maryland’s major sports teams.

Pioneering Mobile Integrated Healthcare

Under Ailiff’s leadership, Procare Ambulance has emerged as a trailblazer in Mobile Integrated Healthcare (MIH), an innovative model that delivers in-home medical care to reduce hospital readmissions and improve patient outcomes. As Maryland’s first and only private EMS provider approved for MIH, Procare has saved thousands of inpatient days, easing the burden on hospitals while enhancing community health.

“Being named a finalist for the EY Entrepreneur Of The Year® award is a reflection of the extraordinary team behind Procare,” said Ailiff. “Our success is rooted in a deep, shared commitment to the patients we serve, the partners we support, and the people who power our mission. This recognition is especially meaningful to me, as my late brother, Geaton DeCesaris, was a past recipient of the Entrepreneur Of The Year® Mid-Atlantic Award. It’s an honor to follow in his footsteps and stand among those shaping the future with vision and impact.”

Award Timeline and National Recognition

Regional winners will be announced on June 18, 2025, at a special awards ceremony in Washington, DC. These winners will then advance to compete for the National Entrepreneur Of The Year Awards, to be presented in November 2025 at the EY Strategic Growth Forum®, a premier gathering of high-growth companies and industry leaders.

Supporting a Legacy of Innovation

The Entrepreneur Of The Year program, founded in 1986, has honored more than 11,000 entrepreneurs across the U.S. and nearly 60 countries worldwide. The awards are produced by EY US, with support from presenting sponsors including PNC Bank, SAP, Marsh USA, and Cresa, LLC. Additional regional sponsors include ADP, Cooley, DLA Piper, and REQ.

A Vision for the Future

Ailiff’s recognition underscores the growing importance of private-sector innovation in healthcare, particularly in preventive and integrated care models. Her leadership at Procare exemplifies how entrepreneurial vision can drive systemic change, improving both patient outcomes and healthcare efficiency.

Join the Celebration

Follow Procare Ambulance’s journey and updates on the Entrepreneur Of The Year awards:

LinkedIn: Procare Ambulance of Maryland, Inc.
Facebook: @ProcareAmbo

About Procare Ambulance of Maryland, Inc.

Procare is one of the leading medical transportation and mobile healthcare providers, specializing in high-acuity interfacility transport, Mobile Integrated Healthcare (MIH), and medical standby services. The company is recognized for its clinical excellence, innovative care models, and commitment to improving healthcare access and outcomes across the Baltimore-Washington region.

Media Contact
Company Name: Procare Ambulance of Maryland, Inc.
Contact Person: Cameron Ailiff
Email: Send Email
Phone: (443) 370-2990
Country: United States
Website: https://procareambulance.com/

Free College Prep Program with Admissions Expert Barbara Connolly

Birmingham, Michigan – High school students and their families are invited to a FREE college preparation event on Thursday, May 22 at 6 PM, where nationally recognized college admissions expert Barbara Connolly, JD, CEP will share invaluable insights to help students excel in today’s competitive application process.

Barbara Connolly, founder of College Choice Counseling®, brings unique expertise as a former admissions reader at the University of Michigan Ross School of Business. With a background as a licensed attorney, Certified Educational Planner (CEP), and professional member of the Independent Educational Consultants Association (IECA), Connolly offers unparalleled insights into the world of college applications. Her TEDx talk, “How College Obsession Can Be a Force for Good,” has garnered nearly 1.5 million views, solidifying her reputation as a trusted voice in the realm of higher education.

What to Expect:

Attendees will receive an hour of expert advice, including:

Trends in college admissions

Proven tips for crafting winning college applications

Strategies for writing compelling essays

Exclusive insights into the University of Michigan admissions process

A live Q&A to answer all your college prep questions

Who Should Attend:

This event is perfect for high school students at any stage of the college admissions journey as well as parents and guidance counselors eager to gain tools and strategies to guide their students toward success.

Why Attend:

With college admissions becoming increasingly competitive, staying ahead with expert guidance can make all the difference. This session will empower attendees with actionable steps to make their applications shine.

Registration Details:

The event is completely free, but space is limited. Register today to secure your spot.

FREE College Prep Registration Form Click Here – College Choice Counseling

https://www.meetup.com/college-counseling-admission-services/events/307326907/?utm_medium=referral&utm_campaign=share-btn_savedevents_share_modal&utm_source=link

Topic: FREE College Prep Program – College Choice Counseling

Time: May 22, 2025 06:00 PM Eastern Time (US and Canada)

Join Zoom Meeting

https://us06web.zoom.us/j/81864592431?pwd=UiKlKaHMf9B3KqulTCsX2Q8jWae2r7.1

Meeting ID: 818 6459 2431

Passcode: 462505

About Barbara Connolly:

Barbara Connolly, JD, CEP, is the founder of College Choice Counseling®, a leading firm specializing in college and graduate school counseling as well as academic and test preparation. A former admissions reader at the University of Michigan Ross School of Business, she has appeared regularly in local and national media, offering insights into college admissions. Connolly holds a BGS from the University of Michigan and a JD from the University of Detroit School of Law.

Don’t miss this valuable opportunity to gain expert advice and set your college application up for success.

Barbara Connolly: How College Obsession Can Be a Force for Good | TED Talk

Media Contact
Company Name: College Choice Counseling
Email: Send Email
Phone: (248) 294-0099
Address:135 N Old Woodward Ave Suite 200
City: Birmingham
State: MI 48009
Country: United States
Website: https://www.collegechoicecounseling.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Free College Prep Program with Admissions Expert Barbara Connolly

Guinness World Record Holder & Ultra-Distance Legend Stan Cottrell Embarks on a 1,000-Mile Run Across Georgia to Honor Veterans & First Responders Promoting Global Unity-Netflix Project

Atlanta, GA – On May 1, 2025, at 1PM, world-renowned ultra-distance runner Stan Cottrell will set out on an extraordinary 1,000-mile journey starting at the GEORGIA STATE CAPITOL across the state of Georgia. Beginning in the northern region, Cottrell will travel southward, reaching both the Florida and Alabama borders, before making his way back north, where his run will finish in the same place he starts in Atlanta, GA, on June 15, 2025. This monumental run is dedicated to honoring veterans and first responders worldwide. In addition, to raising funds for local veteran organizations throughout the state.

As he makes his way across Georgia, Cottrell will stop in multiple cities across Georgia, where he will meet with local mayors for special photo opportunities, celebrating the power of community, resilience, and unwavering support for veterans. These key moments will shine a spotlight on the collective effort to honor those who have served. He receives the 2025 Lifetime Achievement Award from the World Chamber of Commerce and is a Nobel Peace Prize Nominee.

For 40 days, audiences around the world can follow Cottrell’s extraordinary journey in real time, with live coverage on social media, major networks, and multiple digital streaming platforms. Known as the real life “Forrest Gump”. Fans and supporters are invited to tune in, cheer him on, and be part of this historic run, as he pushes the limits of human endurance in tribute to veterans everywhere. This footage will be used for his new Netflix docuseries highlighting his philanthropy efforts, past achievements and the legacy he will leave for the next generations to come.

Special thanks to his donors: Marriot, Hampton Inn Suites, Chick-Fil-A, Super Patch, Crane Hanna Productions, and Graham Family Films Foundation

Donation Link: https://amazingfriendshiprun2024.com/

FOLLOW: IG: @runstanrun2021/ FB: @stancottrell

Media Contact
Company Name: Exhibit Ambush Consulting Management
Email: Send Email
Country: United States
Website: https://amazingfriendshiprun2024.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Guinness World Record Holder & Ultra-Distance Legend Stan Cottrell Embarks on a 1,000-Mile Run Across Georgia to Honor Veterans & First Responders Promoting Global Unity-Netflix Project